PD-168,077

PD-168,077 is a drug that acts as a dopamine agonist, and is selective for the D4 receptor. It has antidepressant effects in animal studies, and has been proposed for potential use in the treatment of conditions such as schizophrenia, Parkinson's disease, and erectile dysfunction.

Pharmacology

PD-168,077 is a selective D4 receptor agonist. The D4 receptor is a G protein-coupled receptor that in humans is encoded by the DRD4 gene. It is a target for drugs which treat schizophrenia and Parkinson disease. Dopamine is the primary neurotransmitter activating D4 receptors.

Medical Uses

PD-168,077 has been proposed for potential use in the treatment of several conditions. These include:

• Schizophrenia: PD-168,077 may have potential in treating schizophrenia due to its action on the D4 receptor, which is believed to be implicated in this condition.
• Parkinson's disease: As a dopamine agonist, PD-168,077 may have potential in treating Parkinson's disease, a condition characterized by the death of dopamine-producing cells.
• Erectile dysfunction: PD-168,077 has been shown to enhance erectile function in animal studies, suggesting potential use in the treatment of erectile dysfunction.

Side Effects

As with any drug, PD-168,077 may have potential side effects. These could potentially include those typically associated with dopamine agonists, such as nausea, vomiting, and hallucinations. However, the specific side effects of PD-168,077 have not been fully studied.

See Also

• Dopamine agonist
• D4 receptor
• Schizophrenia
• Parkinson's disease
• Erectile dysfunction

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia